The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. Prog Neurobiol. 2015;127-128:1-22. doi: 10.1016/j.pneurobio.2015.02.003.

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type-1 diabetes, hepatitis, ...

More information: Matthew R. Brier et al, Unexpected Low Rate of Amyloid‐β Pathology in Multiple Sclerosis Patients, Annals of Neurology (2024). DOI: 10.1002/ana.27027.

If you have trouble speaking or swallowing, speech-language pathology can help. Takeaways. Late-onset multiple sclerosis is a form of the disease in which symptoms develop after age 50.

A study of twins reveals two gut bacteria linked to multiple sclerosis, offering new targets for future treatments.

Multiple sclerosis (MS) ... The pathophysiology of MS likely involves a complex interplay between genetic and environmental factors, which are still incompletely identified.

TOPLINE: Amyloid pathology typical of Alzheimer's disease (AD) is 50% lower in patients with multiple sclerosis (MS) than in those without the condition, an analysis of plasma biomarker data shows ...

Considering the longevity of astrocytes, and their multiple contributions to CNS pathology, the authors suggest that astrocyte immune memory might be a possible mechanism behind chronic neurologic ...

Associations of White Matter and Basal Ganglia Microstructure to Cognitive Fatigue Rate in Multiple Sclerosis. Frontiers in Neurology , 2022; 13 DOI: 10.3389/fneur.2022.911012 Cite This Page : ...

And unlike secondary multiple sclerosis, which arises after many years of RRMS, PPMS is an initial diagnosis. The symptoms and pathophysiology of PPMS differ from other forms, too.

Kessler Foundation study advances knowledge of role of brain pathology and cognitive fatigue in multiple sclerosis Kessler researchers demonstrate relationship between rate of cognitive fatigue in ...

I've been involved in MS care since before any treatments were available. I’m chief operating officer at Can Do Multiple Sclerosis, a nonprofit in the patient advocacy sphere of MS. I’m also a ...